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CLINICAL PRESENTATION
Ovarian cancer is a disease of insidious onset without cardinal
symptoms. Owing to this it tends to present late, by which time
there are often widespread metastases throughout the peritoneal
cavity. In some cases distension is the main symptom and in
others the symptoms are pain, nausea and dyspepsia. Distension
may be due solely to a large tumour, but quite frequently, ascites is
also present. In some cases a large tumour remains encapsulated
and confined to the ovary of origin; in other cases, relatively small-
volume ovarian disease is associated with early metastases,
particularly to the omentum with so-called ‘sago’ seedlings around
the entire peritoneal surface. In a small minority of cases,
breathlessness can be the presenting symptom because of pleural
effusion secondary to peritoneal ascites.
DIAGNOSIS AND TREATMENT
Ovarian cancer is often diagnosable clinically by the detection
of a large abdomino-pelvic mass with ascites and characteristic
nodularity felt in the Pouch of Douglas anterior to the rectum.
A careful history will often reveal no gastrointestinal
symptoms, which makes a colonic or gastric tumour much less
likely.
Over the past 15–20 years routine use of ultrasound has resulted
in an unexpected diagnosis being made in women being
investigated for vague abdominal pain and gastrointestinal
symptoms. CA125, a monoclonal antibody detectable in serum,
is usually elevated in ovarian cancer; almost invariably in cases of
serous tumours but seldom in mucinous tumour. It is a valuable
tumour marker and ovarian cancer is likely in cases of CA125 in
excess of 1000iuml
1, with characteristic ultrasound findings of a
solid/cystic mass in the pelvis and ascitic fluid. Certainty regarding
the diagnosis is either made at laparotomy or by radiologically
guided biopsy (e.g., Trucut).
Treatment of ovarian cancer involves a combination of
surgery and chemotherapy, the latter being principally responsible
for improved survival seen over the past 10 years. Surgery
may be curative for the majority of early-stage cancers but these
account for a small minority of cases overall. In many cases,
surgery is an exercise in debulking, which has been considered
worthwhile, particularly if the residual disease is confined to
nodules of less than 1cm. The importance of debulking has been
debated for years. There is no doubt that maximally debulked
women survive longer than those with bulk residual disease but
what is unresolved is whether debulkable tumours are more
chemosensitive and therefore, have a better prognosis. Never-
theless, ‘upfront’ primary surgery remains the international
standard of care.
Chemotherapy using platinum is recommended in most cases,
with the exception of stage 1a disease confined to the capsule. In
recent years chemotherapy has been increasingly used before
surgery in cases where women are ill, unfit for surgery and/or
where the prospects for debulking seem to be poor. Ongoing trials
will determine whether surgery ‘upfront’ or delayed after some
chemotherapy is more effective.
INTERPRETATION OF SURVIVAL PATTERNS
The overall improvement in 1-year survival between the mid 1980s
and mid 1990s is probably because of increased access to
platinum-based chemotherapy. In ovarian cancer, 1-year survival
is dependant on optimal primary therapy. It is widely recognised
that platinum chemotherapy is the most effective treatment for
advanced disease. Carboplatin and taxol in combination will
achieve response rates of 70%.
The improvement in 5-year survival is partly because of more
widespread access to optimal primary treatment, but also reflects a
more determined effort to re-treat recurrent disease. It has become
clear that women who relapse more than 12 months following
initial platinum-based chemotherapy may remain platinum
sensitive and even further recurrences may be treated with other
drug combinations.
Ovarian cancer is, therefore, becoming a more controllable
chronic disease, although cure remains elusive in most cases.
The rise in 5-year survival in some respects represents the fact of
the United Kingdom catching up with the best practices in other
countries. In the early 1990s insufficient specialist care meant that
survival in ovarian cancer lagged behind other countries but that
has been addressed with the Cancer Plan, and now women in the
United Kingdom are treated by expert specialist teams. The rise in
10-year survival reflects what has been said above about treatment
of recurrent disease and longer-term control.
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The deprivation gap at 1 year can probably be explained by a
greater proportion of women in deprived communities having
advanced disease and certainly in the past, poorer access to
optimal treatment. This would have resulted in a higher
proportion of treatment failures. Better access to specialist
treatment has seen this gap close. The absence of a deprivation
gap for 5-year survival is reassuring. It almost certainly reflects
proportions of women with more chemosensitive tumours, with a
longer time to relapse and higher response rates for recurrent
disease. It probably also reflects improved access to specialist
treatment and differences in comorbidity between the richer and
poorer seem not to have an impact on survival.
OVERALL COMMENT
As ovarian cancer presents late, there has been a great deal of
research into ovarian cancer screening. There is no pre-malignant
phase, which can be recognised; but CA125 combined with
ultrasound may be capable of detecting disease at an earlier, and
hence more curable, stage. There is little evidence for this so far,
but an ongoing very large randomised trial (UKCTOCS) will
determine the effectiveness and cost effectiveness of ovarian cancer
screening within 5 years.
As far as overall prognosis is concerned there is the prospect of
continuing lengthening of survival, especially using newer targeted
therapies. A recent clinical report from the NIH drew attention to
increased survival with intraperitoneal chemotherapy, although
the current regimens are rather toxic. A new strategy being
evaluated in clinical trials, which could lengthen remission, is the
use of biological drugs, such as anti-angiogeneic agents as
maintenance therapy.
As the effectiveness of medical therapy increases the role of
surgery may diminish, being used increasingly as a procedure to
follow chemotherapy response rather than an initial procedure.
Overall, incidence may fall as the ‘baby boomers’, who have used
the oral contraceptive pill for many years, become postmenopausal
and epidemiologically appear to be at reduced risk of ovarian
cancer.
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